Fyremadel (F)
Fyremadel (F)
Each pre-filled syringe contains 0.25 mg of ganirelix (as acetate) in 0.5 ml aqueous solution
Fyremadel 250mcg solution for injection in pre-filled syringe is indicated for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
In clinical studies ganirelix was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.
Ganirelix should be administered subcutaneously, preferably in the upper leg. The injection site should be varied to prevent lipoatrophy. The patient or her partner may perform the injections of ganirelix themselves, provided that they are adequately instructed and have access to expert advice.
In clinical studies ganirelix was used with recombinant human follicle stimulating hormone (FSH) or corifollitropin alfa, the sustained follicle stimulant.
Ganirelix should be administered subcutaneously, preferably in the upper leg. The injection site should be varied to prevent lipoatrophy. The patient or her partner may perform the injections of ganirelix themselves, provided that they are adequately instructed and have access to expert advice.
Available on request.
Available on request.
- Form:
- Syringe (Pre-filled)
- Fridge-line:
- No
- Marketing Authorisation:
- PL-Available on Request
- Toxin:
- No
- POM:
- Yes
- Legal Category:
- POM
- Filler:
- No
- Storage Temperature:
- N/A
- Manufacturer:
- N/A
- Click here to view more info.